← Back

Changchun BCHT Biotechnology Co. A

Changchun BCHT Biotechnology Co. Ltd. is a biopharmaceutical company engaged in the research, development, production, and sale of human vaccines in China and internationally. Its products include a varicella vaccine, a nasal spray influenza vaccine, a herpes zoster vaccine, and a liquid nasal spray influenza vaccine. The company also provides therapeutic biological products and cargo transport services, including general and special cargo road transport and import and export of goods and technology. Founded in 2004, it is based in Changchun, China.

Price · split & dividend adjusted
News & notes moving 688276.CG
China
Biotech & Genomic Medicine▲

BCHT's RSV Antibody Combination Therapy Clinical Trial Application Accepted

BCHT announced that the company recently received a notice of acceptance from the National Medical Products Administration for the clinical trial application of a recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination therapy. The product is intended to prevent lower respiratory tract infections caused by RSV in newborns and infants. As a cocktail combination therapy, it has stronger neutralizing activity compared with the four monovalent products already approved in China. The company stated that acceptance of the clinical trial application for this project will help optimize its product structure and enhance long-term profitability, but will not have a significant impact on near-term performance.
Changchun BCHT… ▲
Biotech & Genomic Medicine
About megatrends
Biotech & Genomic Medicine › Antiviral & Infectious-Disease Therapeutics Competition
688276.CG · Technology · Positive NMPA accepted BCHT's clinical trial application for its RSV antibody combination therapy, advancing its product pipeline.
Read original ↗
CLS·13dRead more →
China
688276.CG▼

Baike Bio reports first-half net loss attributable to shareholders of about 52.1 million yuan

Baike Bio released its 2026 semi-annual report, showing a net loss attributable to shareholders of about 52.1 million yuan in the first half, narrowing from a loss of about 73.57 million yuan in the same period last year. The company achieved operating revenue of about 305 million yuan in the first half, up 6.89 percent year on year. Baike Bio is a high-tech biopharmaceutical company specializing in the research, development, production and sales of human vaccines, and currently has approved vaccine products including varicella vaccine, nasal spray influenza vaccine, herpes zoster vaccine and liquid nasal spray influenza vaccine.
Changchun BCHT… ▼
688276.CG · Capital · Negative Reports net loss of 52.1 million yuan in H1, though narrowed from prior year.
Read original ↗
北京商报·46dRead more →
© 2026 MarketDXAsset